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Background: It is already known that high concentration of vi-
tamin C induces apoptosis on tumor cells. However, there is 
no report regarding the function of vitamin C on the modu-
lation of immune susceptibility of cancer. Therefore, we in-
vestigated whether vitamin C can modulate immune sus-
ceptibility of tumor cells, especially on the induction of 
Fas-mediated apoptosis. Methods: First, the optimal concen-
tration of vitamin C, which cannot induce damages on tumor 
cells for 36 hrs. We found that 2 mM of vitamin C did not 
show harmful effect. In addition, the optimal concentration of 
agonistic anti-Fas Abs for 18 hrs was examined. Results: As 
a result, 400 ng/ml of agonistic anti-Fas Abs did not induce 
apoptosis on tumor cells. Next, we tried to find the effect of 
2 mM of vitamin C on the modulation of the susceptibility to 
agonistic anti-Fas Abs. When tumor cells were cultured with 
400 ng/ml of agonistic anti-Fas Abs for 18 hrs, after 
pre-treatment with 2 mM of vitamin C for 24 hrs, viability of 
cells was decreased. Interestingly, we found that the ex-
pression of Fas (CD95) and MHC class I was increased by 
the treatment of vitamin C. Conclusion: Taken together, vita-
min C increases the susceptibility of tumor cells to anti-Fas 




Vitamin C is a well-known anti-tumor agent as well as essen-
tial  nutrients.  According  to  the  report  by  Kang  et  al.,  rela-
tively high concentration of vitamin C (10 mM) induces apop-
tosis of B16 murine melanoma cells via the destruction of mi-
tochondrial membrane potential and release of cytochrome C 
(1).  In  addition,  vitamin  C  effectively  suppresses  the  trans-
location of transferring receptor from cytosol to membrane. 
And it interfere the uptake iron into tumor cells, which is es-
sential process for maintenance of the proliferation of tumor 
cells (2). There are other reports regarding anti-tumor effect 
of relatively low concentration vitamin C, less than 1.0 mM. 
Most of the cases, low concentration of vitamin C could not 
induce extensive apoptosis, but shows the suppression of tu-
mor  proliferation  and  inhibition  of  the  growth  factor  pro-
duction (3). Definite growth arrest of B16 melanoma cells at 
G1 stage by the treatment of 0.2 mM of vitamin C treatment 
was recently reported. It was closely related with the increase 
of p53-p21Waf1/Cip1 and inhibition of CDK2 activity (3,4). 
In the case of SK-MEL-2, human melanoma cell line, it is re-
ported that its proliferation is suppressed by 1 mM of vitamin 
C and it is mediated by the decrease of insulin-like growth 
factor (IGF)-II and its receptor expression (5). In addition, vi-
tamin C could also suppress the production of endogenous The Anti-tumor Activity of Vitamin C
Yeonsil Yu, et al.
211 IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 4 August 2011
molecules, which is essential for their growth and metastasis 
(6-8).
    There are several kinds of immune escape mechanisms in 
tumor. The most well-known mechanism is the down-regu-
lation  of  major  histocompatibility  complex  (MHC)  I  ex-
pression on the surface of tumor cells for the evasion from 
killing by tumor specific cytolytic T lymphocytes (CTLs) (9). 
Down-regulation of Fas (CD95) expression is also known as 
one of the immune escape mechanisms of tumor (10). Taken 
together, CTLs first recognize tumor cells through the MHC 
I on the surface of tumor cells, and then induce the apoptosis 
on tumor cells through the transduction of death signals by 
the interaction between Fas on tumor and Fas ligand (FasL; 
CD154)  on  CTLs.  It  is  generally  known  that  there  are  two 
ways for the induction of apoptosis (11,12). One is mediated 
by tumor necrosis factor (TNF) receptor family such as Fas 
and TRAIL. The other is mediated by the destruction of mem-
brane  potential  in mitochondria, which  is essential  for  ATP 
generation. The former is called as Type I and the latter is 
Type II. However, Type I and II pathways are not totally in-
dependent process. Caspase-8 is activated by the death sig-
nals  through  TNF  receptor  family  and  activated  Caspase-8 
triggers the activation of Type II pathway through the cleav-
age of Bid into truncated form of Bid. Even though it is al-
ready  discovered  that  vitamin  C  induces  Type  II  apoptotic 
pathway in tumor cells in a Caspase-8 independent manner, 
but the enhanced apoptosis by vitamin C via the increase of 
Fas  (CD95)  also  should  be  considered. 
    Therefore,  we  investigated  whether  vitamin  C  could  in-
crease the susceptibility of tumor cells to anti-Fas mAbs and 
the expression of Fas (CD95) and MHC class I on stomach 
cancer  cell  line,  SNU1. 
MATERIALS AND METHODS
Cells 
Human  stomach  cancer  cell  line,  SNU1  was  obtained  from 
American Type Culture Collection (Manassas, VA, USA). Cells 
were cultured in RPMI 1640 supplemented with 2 mM L-gluta-
mine,  100  units/ml  penicillin,  100μg/ml  streptomycin,  and 
10%  heat-inactivated  fetal  bovine  serum.  This  cell  line  was 
used  for  experiments  while  in  the  log  phase  of  growth. 
Vitamin C treatment and measurement of apoptosis 
Human stomach cancer cell line, SNU1 (1×10
6 cells) was cul-
tured in the presence or absence of vitamin C (1 and 2 mM) 
for 36 hrs. The cells were collected and washed twice with 
cold PBS, and then resuspended in 1× binding buffer at a 
concentration  of  1×10
6  cells/ml.  100μl  of  the  solution 
(1×10
5  cells)  was  then  transferred  to  a  5  ml  culture  tube. 
After the addition of 5μl of Annexin V-FITC, cells were in-
cubated at room temperature for 15 min in the dark with gen-
tle  vortexing.  400μl  of  1x  binding  buffer  was  then  added 
to each tube. One microliter of propidium of iodide was add-
ed, prior to analyze with FACSCaliber (BD Pharmingen, San 
Diego,  CA,  USA).  The  Annexin  V-FITC  apoptosis  detection 
kit  was  purchased  from  BD  Pharmingen  (San  Diego,  CA, 
USA).
Trypan blue dye exclusion assay 
Human stomach cancer cell line, SNU1 (1×10
6 cells) was cul-
tured in the presence or absence of vitamin C (1 and 2 mM) 
for  24hrs,  and  then  200  and  400  ng/ml  of  anti-Fas  mAbs 
(CH-11, MBL International, Woburn, MA, USA) were added. 
After further incubation for 18 hrs, cells were harvested and 
washed once with phosphate-buffered saline (PBS). Cell via-
bility was examined by the trypan blue dye exclusion assay. 
Quadruplicate  wells  were  run  for  each  group.
Flow cytometry analysis 
The changing of Fas and MHC I expression on human stom-
ach cancer cell line, SNU1 by the treatment of vitamin C was 
assessed by flow cytometry using the PE conjugated rat an-
ti-human Fas and MHC I mAbs (BD Pharmingen, San Diego, 
CA,  USA).  Briefly,  SNU1  (1×10
6  cells)  was  cultured  in  the 
presence or absence of vitamin C (2 mM) for 3, 6, 12, and 
24 hrs. And then Cells were washed twice with phosphate 
buffered saline (PBS) and then stained with 1μg of anti-hu-
man Fas and MHC I mAbs for 30 min on ice. After washing 
twice with PBS, and cells were analyzed by FACSCaliber (BD 
P h a r m i n g e n ,  S a n  D i e g o ,  C A ,  U S A ) .  
RESULTS
Vitamin C increases the expression of Fas and MHC 
I on the surface of stomach cancer cell line, SNU1
Since we have found that the susceptibility of tumor cells to 
vitamin C is quite diverse in our previous reports (1-8), we 
first  investigated  the  optimal  concentration  of  vitamin  C, 
which does not show cytotoxic effect during the experiment. 
As shown in Fig. 1, we could not observe the extensive apop-
tosis  on  stomach  cancer  cell  line,  SNU1,  when  it  was  in-The Anti-tumor Activity of Vitamin C
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Figure 2. Increase of Fas and MHC I expression on SNU1 by the treatment of vitamin C. The changing of Fas expression (A) and MHC expression
(B) on human stomach cancer cell line, SNU1 by the treatment of vitamin C was assessed by flow cytometry. SNU1 (1×10
6 cells) was cultured
in the presence or absence of vitamin C (2 mM) for 3, 6, 12, and 24 hrs. And then Cells were washed twice with phosphate buffered saline 
(PBS) and then stained with 1μg of PE-conjugated anti-human Fas mAbs or PE-conjugated anti-human MHC I mAbs for 30 min on ice. After 
washing twice with PBS, the cells were analyzed by FACSCaliber. Results are representative of three independent experiments.
Figure 1. Investigation of the optimal doses of vitamin C. Human stomach cancer cell line, SNU1(1×10
6
cells) was in the presence or absence of vitamin C (1 and 2 mM) for 36 hrs. The cells were collected
and washed twice with cold PBS. After the addition of 5μl of Annexin V-FITC, cells were incubated at
room temperature for 15 min in the dark with gentle vortexing. One microliter of propidium of iodide
was added, prior to analyze with FACSCaliber. Results are representative of three independent experiments.
cubated for 36 hrs in the presence of 1 and 2 mM of vitamin 
C. And then we next investigated the changing on Fas and 
MHC I expression on SNU1 after treatment of 2 mM of vita-
min  C  for  indicated  time.  Interestingly,  Fas  expression  was 
increased at 3 hrs after treatment of vitamin C (Fig. 2A). In 
addition,  the  expression  of  MHC  I  on  the  surface  of  SNU1 
was increased at 3 hrs after treatment of vitamin C and it last-
e d  u n t i l l  2 4  h r s  a f t e r  t r e a t m e n t  o f  v i t a m i n  C  ( F i g .  2 B ) .  
Fas mediated apoptosis on stomach cancer cell 
line, SNU1 is increased by the ligation of anti-Fas 
mAbs
As we showed that Fas expression on SNU1 was increased 
b y  th e  tr ea tm e nt  o f v it am in  C in  F ig .  2 A,  t h e c h an g in g  on 
cell  viability  by  the  ligation  of  Fas  with  anti-Fas  mAb  was 
examined. To determine the optimal amount of anti-Fas mAb, 
which cannot induce the extensive apoptosis, the viability of 
cells was examined by trypan blue dye exclusion assay, after 
ligation  of  cells  with  anti-Fas  mAbs  (200∼2,000  ng/ml)  for 
18 hrs. We found that cell viability was more than 90% by The Anti-tumor Activity of Vitamin C
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Figure 3. Synergistic effect of vitamin C with anti-Fas mAb on the changing of cell viability in SNU1. (A) Optimal dose titration of anti-Fas 
mAb; Human stomach cancer cell line, SNU1 (1×10
6 cells) was cultured in the presence or absence of 200 and 400 ng/ml of anti-Fas mAbs
(CH-11) for 18 hrs, and then cells were harvested and washed once with phosphate-buffered saline (PBS). Cell viability was examined by the
trypan blue dye exclusion assay. Quadruplicate wells were run for each group. (B) Human stomach cancer cell line, SNU1 (1×10
6 cells) was 
cultured in the presence or absence of vitamin C (1 and 2 mM) for 24hrs, and then 200 and 400 ng/ml of anti-Fas mAbs (CH-11) were added.
After further incubation for 18 hrs, cells were harvested and washed once with phosphate-buffered saline (PBS). Cell viability was examined 
by the trypan blue dye exclusion assay. Results are representative of three independent experiments. Quadruplicate wells were run for each 
group. Data represent means±SD.
the treatment of 200 and 400 ng/ml of anti-Fas mAbs (Fig. 
3A). And then, we examined the synergistic effect of vitamin 
C and anti-Fas mAb on the changing on viability of SNU1. 
As shown in Fig. 3B, when the cells were pre-treated with 
1 and 2 mM of vitamin C for 24 hrs, prior to ligate with an-
t i - F a s  m A b  f o r  1 8  h r s ,  t h e  v i a b i l i t y  o f  c e l l s  w a s  d e c r e a s e d ,  
when it compared with the control and the cells treated with 
400  ng/ml  of  anti-Fas  mAb  only. 
DISCUSSION
Surgical  excision,  chemotherapy  and  radiotherapy  are  con-
ventional approaches for the treatment of cancer. Surgical ex-
cision is used to get rid of tumor burden. However, it is use-
ful  only  for  the  early  stage  of  cancer,  not  for  metastatic 
cancer. For this reason, chemotherapy or radiotherapy is usu-
a l l y  p e r f o r m e d  f o r  t h e  e l i m i n a t i o n  o f  m e t a s t a t i c  o r  r e s i d u a l  
tumors. However, severe side effects and high costs are major 
problems,  which  should  be  overcome.  Recently,  immuno-
therapy through the enhancing anti-tumor activity of immune 
r e s p o n s e s  i s  a l s o  c o n s i d e r e d  a s  a p p r o a c h  f o r  t h e  t r e a t m e n t  
of cancer (13,14). The basic principle of immunotherapy for 
the  eradication  of  cancer  is  the  activation  of  dendritic  cells 
(DCs), natural killer (NK) cells and tumor infiltrating lympho-
cytes (TILs) (15,16). Therefore, it is thought that the inves-
tigation of the appropriate substances, which is able to induce 
the activation of anti-tumor immune cell subsets, is the best 
way  for  immunotherapy. 
    From this point of view, vitamin C is considered as one 
of the  best candidates,  since  it is already  reported  that NK 
cells show increased anti-tumor activity through the activation 
b y  t h e  t r e a t m e n t  o f  v i t a m i n  C  ( 1 7 ) .  I n  a d d i t i o n ,  w e  f o u n d  
that Vitamin C-treated murine bone marrow-derived dendritic 
cells preferentially drive naïve T cells into Th1 cells by in-
creased IL-12 secretions (18). Even though it is cleared the 
role of vitamin C on the enhancement of anti-tumor immune 
responses, the investigation regarding the increase of immune 
susceptibility of tumor cells is also needed to maximize an-
ti-tumor immune responses by vitamin C. So, we did this ex-
periment whether vitamin C can modulate immune suscepti-
bility  of  tumor  cells.  Among  various  kinds  of  molecule  in-
volved in immune susceptibility of tumor cells, Fas is one of 
the most well-known execute molecules (10). Briefly, cyto-
lytic T lymphocytes (CTLs) first recognize tumor cells through 
the  MHC  I  on  the  surface  of  tumor  cells,  and  then  induce 
the  apoptosis  on  tumor  cells  through  the  transduction  of 
death signals by the interaction between Fas on tumor and 
Fas ligand (FasL; CD154) on CTLs. Thus, down-regulation of 
Fas and MHC I expression is also known as the general char-
acteristics  of  tumors  for  their  escape  from  immune  system 
(10). Therefore, our findings shown here suggest the utility 
of vitamin C as an adjuvant in immunotherapy, since vitamin 
C can act dual function, which are enhancing anti-tumor im-
mune responses and increasing immune susceptibility of tu-The Anti-tumor Activity of Vitamin C
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mor  cell. 
    The physiological vitamin C concentration in human serum 
is known as 70∼85μM (19,20). Serum concentration of vita-
min C is determined by the route of administration. According 
to the report by Sebastian J et al, when 3 grams of vitamin 
C is administered via intravenous injection, vitamin C concen-
tration in serum is reached at 1,700μM, but when it was ad-
ministered via oral route, it is reached at 220μM (21). Even 
though vitamin C used in our experiment (1 and 2 mM) is 
higher than its physiological concentration under normal diet 
condition, it is possible to increase serum vitamin C concen-
tration to 1 and 2 mM by the administration via intravenous 
injection of vitamin C. When we consider that the recent trials 
of anti-cancer therapy by using of vitamin C is done by intra-
venous injection, it seems that the combination approach of 
vitamin  C  and  immunotherapy  or  chemo-/radiotherapy  will 
give  us  the  new  insights  of  cancer  therapy. 
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